Publikation

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Wissenschaftlicher Artikel/Review - 01.01.2016

Bereiche
Schlagwörter (Tags)
PubMed
DOI
Link
Kontakt

Zitation
Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.
Projekt
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Immunother 2016; 39
Veröffentlichungsdatum
01.01.2016
ISSN (Druck)
eISSN (Online)
1537-4513
Seiten
379-382
Verlag
Kurzbeschreibung/Zielsetzung

UNASSIGNED
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.